Farmacokinetiek
The wall formula displayed by this QR code honors Leiden’s research on how the body processes medications.
chdr.nlCrawled Nov 17, 2026
The wall formula displayed by this QR code honors Leiden’s research on how the body processes medications.
CHDR evaluates immune-modulating drugs using challenge models and biomarkers in healthy volunteers and patients.
CHDR uses advanced methods and challenge models, including biomarkers and CNS models, for early-phase drug development.
CHDR’s NeuroKit is a portable CNS test battery for measuring neuropsychological and neurophysiological drug effects in early-phase trials.
CHDR specialises in early-phase clinical trials in healthy volunteers and patients, offering tailored research across therapeutic areas led by in-house experts.
CHDR supports sponsors in early-phase drug development with precision trial services, compliance, and expert guidance.
CHDR offers education programs and training for clinical research professionals in early-phase drug development.
CHDR uses excitability techniques like TMS and nerve stimulation to study CNS drug effects, providing precise insights into neural function and safety.
CHDR develops in vitro, ex vivo, and in vivo immune challenge models to study drug effects on inflammatory pathways in early-phase clinical trials.
CHDR uses metabolic challenges like mixed-meal tests, glucose-insulin clamps, and gluten challenges to assess drug effects on metabolism in early-phase trials.
CHDR’s study shows CBD increases THC’s psychotropic effects and plasma levels without improving analgesia, highlighting important cannabinoid interactions.
CHDR’s IB-Derisk analyser organizes preclinical data to reduce risk and improve safety in early-phase clinical trials.
CHDR opens a new clinical research unit at Medisch Spectrum Twente, advancing drug development and fostering innovation in Twente’s thriving medtech ecosystem.
CHDR’s 2023 highlights report covers record clinical studies, expanded facilities, and drug development breakthroughs.
CHDR collaborates on a €9.5M initiative to drive early-phase drug and vaccine research, enhancing infectious disease control and pandemic preparedness.
CHDR studied the P2X7 antagonist JNJ‑54175446 in major depressive disorder, exploring immune modulation and its effects during a sleep‑deprivation challenge.
CHDR provides updates on clinical trials, scientific breakthroughs, and early-phase drug research developments.
CHDR and LUMC show that the experimental antimalarial drug cabamiquine offers full protection in a controlled malaria infection study, advancing drug research.
CHDR’s team of scientists and clinicians advances early-phase trials and innovative drug development.
Diana Pereira earned her Master of Science in Biomedical Engineering from the University of Minho in 2011. She worked on tissue regeneration research with the University of Galway until 2016.
Eric Houtman (1977) is IT Director at CHDR. He brings more than 25 years of experience in information technology, including over 20 years in the Contract Research Organization (CRO) industry supporting clinical research and drug development.
Meet Matthijs Moerland, Research Director at CHDR, leading immuno-cardiovascular research and in vivo immune challenge models for early-phase drug development.
Meet Maurits Vissers, Head of Operations at CHDR, leveraging pharma experience and clinical pharmacology expertise to advance early-phase drug development.
Pim Gal directs CHDR Twente, overseeing research expansion in the eastern Netherlands. He holds a PhD in clinical pharmacology and specializes in early-phase clinical research.
For 40 years, CHDR has been advancing clinical research and shaping the future of medicine. This milestone celebrates decades of expertise, innovation, and impact.
CHDR is an independent early-phase clinical research organization specializing in Phase 1 and first-in-human trials in Leiden.
CHDR’s clinical research facility supports efficient and innovative early-phase trials. A virtual tour includes labs, a first-in-human unit, and a GMP pharmacy.
CHDR specializes in Phase 1 and first-in-human trials, employing innovative methods and biomarkers.
CHDR’s privacy policy outlines data collection, security, rights, and EU compliance.
CHDR’s whistleblower policy complies with Dutch law and EU Directive 2019/1937 for confidential misconduct reporting.